在COPD患有2型炎症的患者中,尽管吸入三重疗法,但dupilumab安全地减少了恶化
Rodolfo A Estrada1, Diego J Maselli1, Antonio R Anzueto1
1UT Health San Antonio, San Antonio, Texas, USA (R.A.E., D.J.M., A.R.A.).
Annals of internal medicine
|September 4, 2023
概括
杜皮卢马布在2型炎症患者中显著降低了中度至重度的慢性慢性肺炎恶化,这是高色素细胞计数所表明的. 这种生物疗法为这种特定的COPD亚组提供了一种新的治疗选择.
科学领域:
- 肺部病理学 肺部病理学
- 临床试验 临床试验
- 免疫学 免疫学 免疫学
背景情况:
- 慢性阻塞性肺病 (COPD) 是全球主要的健康负担.
- 2型炎症的特征是高氨基细胞,在COPD患者的一个子组中存在.
- 目前的COPD治疗方法并不能在所有患者中充分解决炎症.
研究的目的:
- 评估dupilumab在患有中度至重度COPD和II型炎症的患者中的疗效和安全性.
- 为了确定dupilumab对COPD恶化率的影响.
- 评估dupilumab对肺功能和患者报告结果的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂对照试验 (BOREAS).
- 参与者患有中度至重度的慢性慢性肺炎,血中乙氨基酸细胞计数≥300细胞/μL.
- 患者每隔两周接受dupilumab或安慰剂,持续52周.
主要成果:
- 与安慰剂相比,dupilumab显著降低了中度至重度COPD恶化的发生率 (46%的减少).
- 杜皮卢马布改善了肺功能 (FEV1) 并减少了口服皮质类固醇的使用.
- 杜皮卢马布的安全概况与之前的研究一致,没有发现新的安全问题.
结论:
- 杜皮卢马布有效地减少了COPD患者的恶化,这些患者患有2型炎症.
- 用dupilumab针对2型炎症是针对特定的COPD患者群体的一个有前途的治疗策略.
- 进一步的研究应该探索长期结果和杜皮卢马布在COPD管理中的作用.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:19Antiasthma Drugs: Leukotriene Modifiers
353
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
353
01:17Drugs Used in Lower Respiratory Disorders: Overview
487
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
487
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
342
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
342
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K